Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Baxter
Fish and Richardson
Julphar
Cantor Fitzgerald
Argus Health
US Army
Citi
UBS

Generated: February 19, 2018

DrugPatentWatch Database Preview

Astellas Company Profile

« Back to Dashboard

Summary for Astellas
International Patents:365
US Patents:29
Tradenames:17
Ingredients:13
NDAs:31

Drugs and US Patents for Astellas

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas ADENOCARD adenosine INJECTABLE;INJECTION 019937-002 Oct 30, 1989 AP RX Yes Yes ➤ Sign Up ➤ Sign Up
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes 7,582,617 ➤ Sign Up ➤ Sign Up
Astellas XTANDI enzalutamide CAPSULE;ORAL 203415-001 Aug 31, 2012 RX Yes Yes 7,709,517 ➤ Sign Up Y Y ➤ Sign Up
Astellas ASTAGRAF XL tacrolimus CAPSULE, EXTENDED RELEASE;ORAL 204096-002 Jul 19, 2013 RX Yes No 6,440,458 ➤ Sign Up Y ➤ Sign Up
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes 8,470,801 ➤ Sign Up ➤ Sign Up
Astellas CYCLOCORT amcinonide CREAM;TOPICAL 018116-001 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Sign Up ➤ Sign Up
Astellas PROGRAF tacrolimus CAPSULE;ORAL 050708-003 Aug 24, 1998 AB RX Yes No ➤ Sign Up ➤ Sign Up
Astellas ASTAGRAF XL tacrolimus CAPSULE, EXTENDED RELEASE;ORAL 204096-003 Jul 19, 2013 RX Yes Yes 6,884,433 ➤ Sign Up Y ➤ Sign Up
Astellas CRESEMBA isavuconazonium sulfate POWDER;IV (INFUSION) 207501-001 Mar 6, 2015 RX Yes Yes 6,812,238 ➤ Sign Up Y ➤ Sign Up
Astellas ARISTOCORT triamcinolone TABLET;ORAL 011161-007 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Astellas

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astellas MYCAMINE micafungin sodium INJECTABLE;IV (INFUSION) 021506-003 Jun 27, 2006 5,376,634 ➤ Sign Up
Astellas CYCLOCORT amcinonide CREAM;TOPICAL 018116-002 Approved Prior to Jan 1, 1982 4,158,055 ➤ Sign Up
Astellas ADENOCARD adenosine INJECTABLE;INJECTION 019937-002 Oct 30, 1989 4,673,563 ➤ Sign Up
Astellas CYCLOCORT amcinonide OINTMENT;TOPICAL 018498-001 Approved Prior to Jan 1, 1982 4,158,055 ➤ Sign Up
Astellas PROGRAF tacrolimus INJECTABLE;INJECTION 050709-001 Apr 8, 1994 5,260,301 ➤ Sign Up
Astellas MYCAMINE micafungin sodium INJECTABLE;IV (INFUSION) 021506-002 Mar 16, 2005 6,265,536 ➤ Sign Up
Astellas ADENOSCAN adenosine SOLUTION;IV (INFUSION) 020059-001 May 18, 1995 5,731,296 ➤ Sign Up
Astellas ADENOSCAN adenosine SOLUTION;IV (INFUSION) 020059-002 May 18, 1995 5,731,296 ➤ Sign Up
Astellas MYCAMINE micafungin sodium INJECTABLE;IV (INFUSION) 021506-002 Mar 16, 2005 5,376,634 ➤ Sign Up
Astellas ADENOSCAN adenosine SOLUTION;IV (INFUSION) 020059-001 May 18, 1995 5,070,877 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ASTELLAS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 40 mg ➤ Subscribe 8/31/2016
➤ Subscribe For Injection 50 mg/vial and 100 mg/vial ➤ Subscribe 6/16/2014
➤ Subscribe Extended-release Capsules 0.5 mg, 1 mg, and 5 mg ➤ Subscribe 11/15/2013
➤ Subscribe Injection 0.08 mg/mL, 5 mL vial ➤ Subscribe 4/10/2012
➤ Subscribe Tablets 5 mg and 10 mg ➤ Subscribe 4/8/2009
➤ Subscribe Injection 3 mg/mL, 20 mL and 30 mL vials ➤ Subscribe 4/18/2005
➤ Subscribe Injection 3 mg/mL, 20 mL and 30 mL vials ➤ Subscribe 4/16/2005

Non-Orange Book US Patents for Astellas

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,268,988 Process for preparing an A2A-adenosine receptor agonist and its polymorphs ➤ Sign Up
6,174,896 Quinuclidine derivatives and medicinal composition thereof ➤ Sign Up
8,569,260 N-pyrazole A.sub.2A receptor agonists ➤ Sign Up
7,189,858 N-phenyl substituted carbamoyloxyalkyl-azolium derivatives ➤ Sign Up
8,648,105 Diarylthiohydantoin compounds ➤ Sign Up
7,112,565 Stabilized pharmaceutical composition in lyophilized form ➤ Sign Up
7,732,595 Process for preparing an A.sub.2A-adenosine receptor agonist and its polymorphs ➤ Sign Up
7,151,182 Intermediates for N-substituted carbamoyloxyalkyl-azolium derivatives ➤ Sign Up
7,956,179 Process for preparing an A2A-adenosine receptor agonist and its polymorphs ➤ Sign Up
7,671,192 Process for preparing an A.sub.2A-adenosine receptor agonist and its polymorphs ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Astellas Drugs

Supplementary Protection Certificates for Astellas Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0791 Netherlands ➤ Sign Up PRODUCT NAME: ISAVUCONAZOL ALS ISAVUCONAZONIUM SULFAAT OF ALS EEN ISAVUCONAZONIUM ZOUT MET ELK ANDER FARMACEUTISCH AANVAARDBAAR ANION, NAAR KEUZE IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, HYDRAAT OF SOLVAAT; REGISTRATION NO/DATE: EU/1/15/1036 20151019
133 Luxembourg ➤ Sign Up 91133, EXPIRES: 20181118
00477 Netherlands ➤ Sign Up PRODUCT NAME: REGADENOSON ALSMEDE FARMACEUTISCHE AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/10/643/001 20100906
2013 00065 Denmark ➤ Sign Up PRODUCT NAME: ENZALUTAMID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/13/846 20130625
2013029 Lithuania ➤ Sign Up PRODUCT NAME: ENZALUTAMIDUM; REGISTRATION NO/DATE: EU/1/13/846 20130621
2011 00005 Denmark ➤ Sign Up PRODUCT NAME: REGADENOSON OG SALTE DERAF
2016000011 Germany ➤ Sign Up PRODUCT NAME: ISAVUCONAZONIUM ALS ISAVUCONAZONIUM-SULFAT ODER ALS SALZ MIT EINEM ANDEREN PHARMAZEUTISCH VERTRAEGLICHEN ANION, SOWIE HYDRATE ODER SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/15/1036 20151015
C0071 France ➤ Sign Up PRODUCT NAME: ENZALUTAMIDE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/846 20130625
15/073 Ireland ➤ Sign Up PRODUCT NAME: ISAVUCONAZOLE AS ISAVUCONAZONIUM SULFATE OR AS ISAVUCONAZONIUM SALT WITH ANY OTHER PHARMACEUTICALLY ACCEPTABLE ANION, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, OR SOLVATE; REGISTRATION NO/DATE: EU/1/15/1036 20151015
0130036 00106 Estonia ➤ Sign Up PRODUCT NAME: ENSALUTAMIID;REG NO/DATE: K(2013)4019 (LOPLIK) 25.06.2013
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Harvard Business School
Farmers Insurance
US Department of Justice
Dow
Moodys
Boehringer Ingelheim
Queensland Health
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot